Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01116102 · ClinicalTrials.gov registry record · Phase 4
Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)
A Phase 4 study, sponsored by Baxter Healthcare Corporation.
- Terminated
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT01116102 is a Phase 4 study that was terminated before completion, run by Baxter Healthcare Corporation. The registered enrollment target is 20 participants.
The verdict
NCT01116102, a Phase 4 study, was terminated before completion, sponsored by Baxter Healthcare Corporation.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose is to characterize the in-line pressure profiles associated with several infusion technique factors during subcutaneous (SC) infusion of Lactated Ringer's solution, preceded by recombinant human hyaluronidase (hylenex). The safety and tolerability of hylenex-augmented SC infusion of Lactated Ringer's solution fluid is also being evaluated.
Interventions
- DRUG Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01116102
The ClinicalTrials.gov registry entry for NCT01116102 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxter Healthcare Corporation, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution is the first listed.
NCT01116102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01116102 about?
NCT01116102 is a clinical study titled "Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)". The purpose is to characterize the in-line pressure profiles associated with several infusion technique factors during subcutaneous (SC) infusion of Lactated Ringer's solution, preceded by recombinant human hyaluronidase (hylenex). The safety and tolerability of hylenex-augmented SC infusion of Lact...
What is the current status of trial NCT01116102?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2010-05. Estimated completion is 2010-06.
What interventions are being tested in trial NCT01116102?
The interventions under investigation include: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution (DRUG).
Who is sponsoring clinical trial NCT01116102?
This trial is sponsored by Baxter Healthcare Corporation, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.